Home
RLAY
RLAY News

Latest Relay Therapeutics Inc. (RLAY) News on April 1, 2025

Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines!

Insider Monkey

a day ago

Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines!

Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)

Zacks

a month ago

Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

GlobeNewswire

a month ago

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnings

GuruFocus.com

a month ago

What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnings

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire

a month ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

GlobeNewswire

a month ago

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

MT Newswires

2 months ago

Relay Therapeutics Insider Sold Shares Worth $268,339, According to a Recent SEC Filing

MT Newswires

2 months ago

Relay Therapeutics Insider Sold Shares Worth $362,298, According to a Recent SEC Filing

Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target

Insider Monkey

2 months ago

Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target

We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate

Simply Wall St.

2 months ago

We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

3 months ago

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now?

Insider Monkey

3 months ago

Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now?

Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade

Zacks

3 months ago

Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade

MT Newswires

3 months ago

Relay Therapeutics Insider Sold Shares Worth $500,000, According to a Recent SEC Filing

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory

Insider Monkey

4 months ago

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory

MT Newswires

4 months ago

Relay Therapeutics Says RLY-2608 With Fulvestrant Data Shows 'Clinically Meaninful' Metastatic Breast Cancer Survival

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

GlobeNewswire

4 months ago

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

4 months ago

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)

Zacks

4 months ago

After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)

Relay Therapeutics price target lowered to $18 from $19 at Leerink

TipRanks

4 months ago

Relay Therapeutics price target lowered to $18 from $19 at Leerink

Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now?

Insider Monkey

4 months ago

Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now?

MT Newswires

4 months ago

Relay Therapeutics Signs Global Licensing Deal With Elevar Therapeutics for Lirafugratinib

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

GlobeNewswire

4 months ago

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

GlobeNewswire

4 months ago

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround

Zacks

4 months ago

Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround

Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround

Zacks

4 months ago

Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround

Relay Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

5 months ago

Relay Therapeutics to Participate in Upcoming Investor Conferences

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

GlobeNewswire

5 months ago

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

GlobeNewswire

5 months ago

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses

Simply Wall St.

5 months ago

Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses

Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?

Zacks

6 months ago

Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?

Why Relay Therapeutics Plummeted by Nearly 14% Today

Motley Fool

7 months ago

Why Relay Therapeutics Plummeted by Nearly 14% Today

MT Newswires

7 months ago

Sector Update: Health Care

MT Newswires

7 months ago

Relay Therapeutics Prices $200 Million Common Stock Offering; Shares Fall Pre-Bell

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire

7 months ago

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Relay Stock Soars on Upbeat Data From Breast Cancer Study

Zacks

7 months ago

Relay Stock Soars on Upbeat Data From Breast Cancer Study

MT Newswires

7 months ago

Jefferies Upgrades Relay Therapeutics to Buy From Hold, Price Target is $16

MT Newswires

7 months ago

Oppenheimer Downgrades Relay Therapeutics to Perform From Outperform, Price Target is $24

MT Newswires

7 months ago

Relay Therapeutics Starts $200 Million Public Share Offering

Relay Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire

7 months ago

Relay Therapeutics Announces Proposed Public Offering of Common Stock

MT Newswires

7 months ago

Barclays Raises Price Target on Relay Therapeutics to $17 From $14, Keeps Overweight Rating

MT Newswires

7 months ago

Top Midday Gainers

Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients

Benzinga

7 months ago

Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients

MT Newswires

7 months ago

Relay Therapeutics Shares Rise Premarket on Positive Interim Data for RLY-2608 Breast Cancer Treatment

Relay breast cancer drug shows potential in early trial

BioPharma Dive

7 months ago

Relay breast cancer drug shows potential in early trial

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

GlobeNewswire

7 months ago

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024

GlobeNewswire

7 months ago

Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024

MT Newswires

8 months ago

Oppenheimer Trims Relay Therapeutics Price Target to $24 From $25, Maintains Outperform Rating

Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

GlobeNewswire

8 months ago

Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024

GlobeNewswire

8 months ago

Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024

We're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate

Simply Wall St.

8 months ago

We're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate

MT Newswires

8 months ago

JMP Securities Cuts Price Target on Relay Therapeutics to $21 From $24, Maintains Market Outperform Rating

MT Newswires

8 months ago

HC Wainwright Adjusts Price Target on Relay Therapeutics to $18 From $20, Maintains Buy Rating

Caribou lays off staff; Roche walks away from Relay

BioPharma Dive

8 months ago

Caribou lays off staff; Roche walks away from Relay

MT Newswires

9 months ago

Relay Therapeutics Get Collaboration, License Deal Terminated With Genentech

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities

GlobeNewswire

10 months ago

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)

Motley Fool

10 months ago

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans

CNW Group

10 months ago

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike

Investor's Business Daily

10 months ago

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike

EPCOR and HAWSCo Enter Ownership Transfer Agreement

CNW Group

10 months ago

EPCOR and HAWSCo Enter Ownership Transfer Agreement

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate

GlobeNewswire

10 months ago

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate

Southwest Airlines stock pops on report of Elliott's $2B stake

Yahoo Finance Video

10 months ago

Southwest Airlines stock pops on report of Elliott's $2B stake

Business Wire

10 months ago

Form 8.3 - Virgin Money UK plc

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event

GlobeNewswire

10 months ago

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event

MT Newswires

10 months ago

Relay Therapeutics to Collaborate With Pfizer to Evaluate Metastatic Breast Cancer Treatment

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608

GlobeNewswire

10 months ago

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608

Relay Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

10 months ago

Relay Therapeutics to Participate in Upcoming Investor Conferences

Relay Therapeutics to Host New Program and Platform Event on June 6, 2024

GlobeNewswire

a year ago

Relay Therapeutics to Host New Program and Platform Event on June 6, 2024

MT Newswires

a year ago

Barclays Upgrades Relay Therapeutics to Overweight From Equalweight With $15 Price Target

MT Newswires

a year ago

Oppenheimer Adjusts Relay Therapeutics Price Target to $25 From $33, Maintains Outperform Rating

Relay Therapeutics First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

a year ago

Relay Therapeutics First Quarter 2024 Earnings: Beats Expectations

Relay Therapeutics Outperforms Revenue Expectations in Q1 2024

GuruFocus.com

a year ago

Relay Therapeutics Outperforms Revenue Expectations in Q1 2024

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates

Zacks

a year ago

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights

GlobeNewswire

a year ago

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024

GlobeNewswire

a year ago

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024

Relay Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Relay Therapeutics to Participate in Upcoming Investor Conferences

11 Oversold Biotech Stocks To Buy Right Now

Insider Monkey

a year ago

11 Oversold Biotech Stocks To Buy Right Now

Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?

Zacks

a year ago

Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?

Relay Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewswire

a year ago

Relay Therapeutics to Participate in Three Upcoming Investor Conferences

Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?

Zacks

a year ago

Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?

Relay Therapeutics Full Year 2023 Earnings: Beats Expectations

Simply Wall St.

a year ago

Relay Therapeutics Full Year 2023 Earnings: Beats Expectations

GuruFocus.com

a year ago

Relay Therapeutics Inc (RLAY) Reports Full Year 2023 Financial Results and Corporate Highlights

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

GlobeNewswire

a year ago

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

GlobeNewswire

a year ago

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

a year ago

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?

Zacks

a year ago

Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?

Palmer: How Charles Omenihu's torn ACL affects Chiefs' DL rotation vs. SF's run game

NFL Highlights

a year ago

Palmer: How Charles Omenihu's torn ACL affects Chiefs' DL rotation vs. SF's run game

Purdy on how SF's experience with 'backs against wall' helps in adversity

NFL Highlights

a year ago

Purdy on how SF's experience with 'backs against wall' helps in adversity

Zacks

a year ago

Sovos Brands (SOVO) and Vertiv (VRT) Are Aggressive Growth Stocks

Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Starbucks slashes sales guidance after missing the mark in Q1 earnings

Yahoo Finance

a year ago

Starbucks slashes sales guidance after missing the mark in Q1 earnings

PR Newswire

a year ago

Century Communities Announces Brand-New Homes Available in Fresno, California

Ultra Clean Announces Q4 2023 Earnings Call and Webcast

PR Newswire

a year ago

Ultra Clean Announces Q4 2023 Earnings Call and Webcast

When Will Bloom Energy Corporation (NYSE:BE) Breakeven?

Simply Wall St.

a year ago

When Will Bloom Energy Corporation (NYSE:BE) Breakeven?

Zacks Industry Outlook Highlights American Water Works, California Water Service Group, SJW Group and Consolidated Water

Zacks

a year ago

Zacks Industry Outlook Highlights American Water Works, California Water Service Group, SJW Group and Consolidated Water

Chief Operating Officer Kirk Jensen Sells 12,802 Shares of Sovos Brands Inc

GuruFocus.com

a year ago

Chief Operating Officer Kirk Jensen Sells 12,802 Shares of Sovos Brands Inc

Oscar Health, Inc. 2023 Fourth Quarter and Full Year Earnings Conference Call

Business Wire

a year ago

Oscar Health, Inc. 2023 Fourth Quarter and Full Year Earnings Conference Call

New Strong Buy Stocks for January 18th

Zacks

a year ago

New Strong Buy Stocks for January 18th

Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential

TipRanks

a year ago

Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential

When Will Rocket Lab USA, Inc. (NASDAQ:RKLB) Become Profitable?

Simply Wall St.

a year ago

When Will Rocket Lab USA, Inc. (NASDAQ:RKLB) Become Profitable?

Share on Social Networks: